HK1207004A1 - 治療輕度和中度阿爾茨海默病的方法 - Google Patents

治療輕度和中度阿爾茨海默病的方法 Download PDF

Info

Publication number
HK1207004A1
HK1207004A1 HK15107776.8A HK15107776A HK1207004A1 HK 1207004 A1 HK1207004 A1 HK 1207004A1 HK 15107776 A HK15107776 A HK 15107776A HK 1207004 A1 HK1207004 A1 HK 1207004A1
Authority
HK
Hong Kong
Prior art keywords
day
subject
phenoxy
hydrochloride
achei
Prior art date
Application number
HK15107776.8A
Other languages
English (en)
Chinese (zh)
Inventor
．奧蘭迪
C.奥兰迪
．克拉克
D.J.克拉克
．格裡梅斯
I.M.格里梅斯
．瓦爾卡西-洛佩茲
M.C.瓦尔卡西-洛佩兹
．考斯圖拉
M.J.考斯图拉
Original Assignee
Vtv治疗有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv治疗有限责任公司 filed Critical Vtv治疗有限责任公司
Publication of HK1207004A1 publication Critical patent/HK1207004A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
HK15107776.8A 2012-10-05 2013-10-02 治療輕度和中度阿爾茨海默病的方法 HK1207004A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
US61/710,229 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK19132980.4A Addition HK40009571A (en) 2012-10-05 2015-08-11 Treatment of mild and moderated alzheimer's disease

Publications (1)

Publication Number Publication Date
HK1207004A1 true HK1207004A1 (zh) 2016-01-22

Family

ID=49354960

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107776.8A HK1207004A1 (zh) 2012-10-05 2013-10-02 治療輕度和中度阿爾茨海默病的方法

Country Status (15)

Country Link
EP (1) EP2903606A1 (enExample)
JP (2) JP6566868B2 (enExample)
KR (1) KR20150064743A (enExample)
CN (2) CN104703592A (enExample)
AU (2) AU2013327450B2 (enExample)
BR (1) BR112015007641A8 (enExample)
CA (1) CA2886785C (enExample)
EA (1) EA201590687A1 (enExample)
HK (1) HK1207004A1 (enExample)
IL (1) IL237730B (enExample)
IN (1) IN2015DN03734A (enExample)
MX (1) MX377733B (enExample)
NZ (2) NZ739521A (enExample)
SG (2) SG11201502210VA (enExample)
WO (1) WO2014055588A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114031687B (zh) * 2021-11-12 2022-06-07 深圳市人民医院 靶向rage的纳米抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US8933040B2 (en) * 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
SG10201702648YA (en) 2017-04-27
IL237730B (en) 2018-10-31
CN104703592A (zh) 2015-06-10
KR20150064743A (ko) 2015-06-11
BR112015007641A8 (pt) 2018-04-03
MX377733B (es) 2025-03-11
AU2013327450B2 (en) 2018-07-12
NZ739521A (en) 2019-06-28
CA2886785C (en) 2022-06-07
CA2886785A1 (en) 2014-04-10
JP6566868B2 (ja) 2019-08-28
MX2015003732A (es) 2015-09-23
EP2903606A1 (en) 2015-08-12
BR112015007641A2 (pt) 2017-07-04
AU2013327450A1 (en) 2015-05-14
AU2018203434A1 (en) 2018-06-07
IN2015DN03734A (enExample) 2015-09-18
WO2014055588A1 (en) 2014-04-10
JP6894940B2 (ja) 2021-06-30
JP2015535850A (ja) 2015-12-17
EA201590687A1 (ru) 2015-09-30
NZ705813A (en) 2018-02-23
SG11201502210VA (en) 2015-04-29
JP2019163301A (ja) 2019-09-26
CN110292638A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
JP2019163301A (ja) 軽度および中等度アルツハイマー病の処置
AU2006226811B2 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
CA2829947C (en) Dosing regimens for the treatment of fabry disease
US20220040126A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
Chen et al. Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
EP3607942B1 (en) Medicament and method of diagnosis
EP3972604B1 (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
US20190142803A1 (en) Treatment of Mild and Moderate Alzheimer's Disease
Lubanda et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
Dahl et al. Safety and tolerability of once-daily tiotropium Respimat® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis
US20210113495A1 (en) Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
Billin et al. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury
Kang et al. Xuebijing injection protects sepsis induced myocardial injury by mediating TLR4/NF-κB/IKKα and JAK2/STAT3 signaling pathways
HK40009571A (en) Treatment of mild and moderated alzheimer's disease
EP3478364A1 (en) Diagnostic or predictor of relapsing remitting multiple sclerosis
Zhao et al. Effect of Shenfu injection on porcine renal function after cardiopulmonary resuscitation
Yates et al. Delayed treatment of secondary degeneration following acute optic nerve transection using a combination of ion channel inhibitors
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
Chopra et al. Effect of Finerenone on the KCCQ in patients with HFmrEF/HFpEF: a prespecified analysis of FINEARTS-HF
Li et al. Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis
Zaremba-Pechmann et al. Ronald Dahl, Michael Engel b, Daniel Dusser c, David Halpin d, Huib AM Kerstjens e
HK40061328B (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
Sankhwar et al. ASSESS THE EFFICACY OF FUROSAP®, A TESTOSTERONE BOOSTER SUPPLEMENT, IN HUMAN VOLUNTEERS: AN ADD-ON STUDY